Following a recent endorsement from the EMA, Biocon has moved to secure launch dates for its Pebrilzo biosimilar to Perjeta across the world, including a Q1 2027 launch in Europe. But with Organon already holding EU and US approvals for its own Henlius-partnered pertuzumab Poherdy, a showdown looms.